These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035 [TBL] [Abstract][Full Text] [Related]
12. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system. van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608 [TBL] [Abstract][Full Text] [Related]
13. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference? Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154 [TBL] [Abstract][Full Text] [Related]
14. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638 [TBL] [Abstract][Full Text] [Related]
15. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281 [TBL] [Abstract][Full Text] [Related]
16. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States. Pavlovich CP; Trock BJ; Sulman A; Wagner AA; Mettee LZ; Su LM J Urol; 2008 Mar; 179(3):917-21; discussion 921-2. PubMed ID: 18207191 [TBL] [Abstract][Full Text] [Related]
17. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576 [TBL] [Abstract][Full Text] [Related]
18. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616 [TBL] [Abstract][Full Text] [Related]
19. Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically. Louie-Johnsun M; Neill M; Treurnicht K; Jarmulowicz M; Eden C BJU Int; 2009 Nov; 104(10):1501-4. PubMed ID: 19426187 [TBL] [Abstract][Full Text] [Related]
20. Outcomes for men younger than 50 years undergoing radical prostatectomy. Twiss C; Slova D; Lepor H Urology; 2005 Jul; 66(1):141-6. PubMed ID: 15992906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]